A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.
Medscape Medical News
Original Article: Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD